Stoneridge Investment Partners’s TherapeuticsMD TXMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-751
| Closed | -$14K | – | 107 |
|
|
2022
Q1 | $14K | Hold |
751
| – | – | 0.01% | 99 |
|
|
2021
Q4 | $13K | Hold |
751
| – | – | 0.01% | 110 |
|
|
2021
Q3 | $28K | Hold |
751
| – | – | 0.01% | 109 |
|
|
2021
Q2 | $45K | Hold |
751
| – | – | 0.02% | 102 |
|
|
2021
Q1 | $50K | Hold |
751
| – | – | 0.03% | 103 |
|
|
2020
Q4 | $45K | Hold |
751
| – | – | 0.03% | 103 |
|
|
2020
Q3 | $59K | Buy |
751
+245
| +48% | +$19.5K | 0.04% | 105 |
|
|
2020
Q2 | $32K | Hold |
506
| – | – | 0.01% | 111 |
|
|
2020
Q1 | $27K | Hold |
506
| – | – | 0.01% | 113 |
|
|
2019
Q4 | $61K | Hold |
506
| – | – | 0.02% | 129 |
|
|
2019
Q3 | $92K | Hold |
506
| – | – | 0.03% | 124 |
|
|
2019
Q2 | $66K | Hold |
506
| – | – | 0.02% | 111 |
|
|
2019
Q1 | $123K | Hold |
506
| – | – | 0.04% | 111 |
|
|
2018
Q4 | $96K | Hold |
506
| – | – | 0.03% | 119 |
|
|
2018
Q3 | $166K | Hold |
506
| – | – | 0.04% | 123 |
|
|
2018
Q2 | $158K | Sell |
506
-1,661
| -77% | -$507K | 0.03% | 111 |
|
|
2018
Q1 | $528K | Sell |
2,167
-747
| -26% | -$210K | 0.09% | 110 |
|
|
2017
Q4 | $880K | Hold |
2,914
| – | – | 0.14% | 98 |
|
|
2017
Q3 | $771K | Sell |
2,914
-1,001
| -26% | -$289K | 0.12% | 112 |
|
|
2017
Q2 | $1.03M | Sell |
3,915
-5,434
| -58% | -$1.36M | 0.15% | 114 |
|
|
2017
Q1 | $3.37M | Sell |
9,349
-953
| -9% | -$295K | 0.45% | 83 |
|
|
2016
Q4 | $2.97M | Buy |
10,302
+1,166
| +13% | +$361K | 0.4% | 89 |
|
|
2016
Q3 | $3.11M | Sell |
9,136
-202
| -2% | -$73.8K | 0.45% | 84 |
|
|
2016
Q2 | $3.97M | Sell |
9,338
-42
| -0.4% | -$17.3K | 0.59% | 50 |
|
|
2016
Q1 | $3M | Sell |
9,380
-524
| -5% | -$179K | 0.44% | 79 |
|
|
2015
Q4 | $5.13M | Sell |
9,904
-293
| -3% | -$108K | 0.69% | 48 |
|
|
2015
Q3 | $2.99M | Buy |
10,197
+2,506
| +33% | +$891K | 0.42% | 67 |
|
|
2015
Q2 | $3.02M | Sell |
7,691
-3,230
| -30% | -$1.14M | 0.37% | 78 |
|
|
2015
Q1 | $3.3M | Buy |
10,921
+80
| +0.7% | +$19.5K | 0.39% | 84 |
|
|
2014
Q4 | $2.41M | Buy |
10,841
+1,777
| +20% | +$367K | 0.32% | 107 |
|
|
2014
Q3 | $2.1M | Buy |
9,064
+610
| +7% | +$154K | 0.31% | 109 |
|
|
2014
Q2 | $1.87M | Buy |
+8,454
| New | +$1.88M | 0.28% | 119 |
|
|
2014
Q1 | – | Sell |
-2,704
| Closed | -$704K | – | 229 |
|
|
2013
Q4 | $704K | Buy |
+2,704
| New | +$592K | 0.14% | 103 |
|
Other funds holding TXMD
RCMNY
E
GF
Stoneridge Investment Partners's TXMD Position: Q2 2022 in Review
Stoneridge Investment Partners sold out of TherapeuticsMD (TXMD) in Q2 2022, closing a stake of 751 shares — an estimated $14K sold.
Stoneridge Investment Partners first reported a position in TXMD in Q4 2013 and held it in 33 quarters. The position peaked at $5.13M in Q4 2015. 53 funds tracked by Wall St. Rank hold TXMD as of Q2 2022.
- Stoneridge Investment Partners reported no remaining TherapeuticsMD position as of Q2 2022 after selling out during the quarter.
- Stoneridge Investment Partners sold 751 TherapeuticsMD shares in Q2 2022, an estimated $14K.
- Stoneridge Investment Partners first reported a position in TherapeuticsMD in Q4 2013 and held it in 33 quarters.
- Stoneridge Investment Partners's TherapeuticsMD position peaked at $5.13M in Q4 2015.
- 53 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2022.
Based on Stoneridge Investment Partners's 13F filing for Q2 2022, filed 1 Aug 2022.